Search Within

Department of Medicine

Formats
  1. Journal Article (19618)
  2. Meeting Abstract (16046)
  3. Review (1158)
  4. Book Section (934)
  5. Editorial (611)
  6. Research Letter (316)
  7. Conference Paper (301)
  8. Guidelines (298)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22348)
  2. Hematologic Malignancies, Division of (13287)
  3. Center for Hematologic Malignancies (11069)
  4. GSK Faculty (10653)
  5. Survivorship Research (9346)
  6. Division of Subspecialty Medicine (7554)

More Groups

People
  1. Robert Motzer (1249)
  2. Howard Scher (1133)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (906)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1118)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2291)
  6. Nature Publishing Group (2121)

More Publishers

Results (39669)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Intrinsic MyD88-mediated signals drive CD4+T cell differentiation during aspergillus fumigataus infection
    Meeting Abstract

    Rivera, A.; Ro, G.; Leiner, I.; Pamer, E. G.
    Journal of Immunology (2006)

    Fulltext@MSK | Save
  • Phase II trial of extended-dosing temozolomide in patients with melanoma
    Meeting Abstract

    Rietschel, P.; Ejadi, S.; Wolchok, J.; Krown, S.; Gerst, S.; Jungbluth, A. A.; Busam, K.; Smith, K.; Panageas, K.; Chapman, P.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Prospective FDG-PET and CT assessment of discontinuation of erlotinib (E) or gefitinib (G) in patients with EGFR TKI sensitive non-small cell lung cancer (NSCLC) who subsequently progress radiographically on E or G ("acquired resistance") followed by re-initiation of E or G and the subsequent addition of everolimus (RAD001)
    Meeting Abstract

    Riely, G. J.; Kris, M. G.; Schwartz, L. H.; Akhurst, T.; Zhao, B.; Milton, D. T.; Moore, E.; Tyson, L.; Pao, W.; Miller, V. A.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Long-term neck control rates after complete response to chemoradiation in patients with advanced head and neck cancer
    Meeting Abstract

    Rengan, R.; Pfister, D. G.; Lee, N. Y.; Kraus, D.; Shah, J.; Shaha, A.; Ben-Porat, L.; Zelefsky, M. J.
    International Journal of Radiation Oncology, Biology, Physics (2006)

    Fulltext@MSK | Save
  • Long term clinical benefit of lenalidomide (Revlimid) treatment in patients with myelodysplastic syndrome without del 5q cytogenetic abnormalities
    Meeting Abstract

    Raza, A.; Reeves, J. E.; Feldman, E. J.; Deeg, H. J.; Dreisbach, L.; Schiffer, C. A.; Shammo, J. M.; Klimek, V. M.; Greenberg, P. L.; Bennett, J. M.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • The Stanford experience with utilizing the new WHO classification of cutaneous lymphomas for cutaneous B cell lymphoma
    Meeting Abstract

    Reddy, S.; Kohler, S.; Horwitz, S.; Sutherland, K.; Hoppe, R. T.; Kim, Y. H.
    Journal of Investigative Dermatology (2006)

    Fulltext@MSK | Save
  • Increased dose intensity of SGN-33, a humanized monoclonal antibody targeting CD33, is active and well-tolerated in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)
    Meeting Abstract

    Raza, A.; Jurcic, J. G.; Roboz, G. J.; Stephenson, J. J.; Rarick, M. U.; Wood, B. L.; Grove, L. E.; Sieyers, E. L.; Drachman, J. G.
    Blood (2006)

    Fulltext@MSK | Save
  • Treatment outcome after induction chemotherapy before allogeneic hematopoietic SCT in patients with advanced MDS
    Meeting Abstract

    Ramos, C. A.; Jakubowski, A. A.; Boulad, F.; Papadopoulos, E. B.; Young, J. W.; Kernan, N. A.; Perales, M. A.; Small, T. N.; Berman, E.; O'Reilly, R. J.; more...
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Intensity-modulated radiation therapy (IMRT) versus conventional radiotherapy using delayed accelerated concomitant boost (CBRT) for patients with locally advanced oropharyngeal carcinoma
    Meeting Abstract

    Puri, D. R.; Lee, N. Y.; De Arruda, F. F.; Wolden, S. L.; Narayana, A.; Venkatraman, E. S.; Kraus, D. H.; Shah, J. P.; Pfister, D. G.; Zelefsky, M. J.
    International Journal of Radiation Oncology, Biology, Physics (2006)

    Fulltext@MSK | Save
  • B-RAF mutation is associated with altered patterns of negative feedback of MAPK signaling that correlate with increased output of the pathway and increased sensitivity to MEK inhibition
    Meeting Abstract

    Pratilas, C.; Grbovic, O.; Zhao, H.; Viale, A.; Solit, D.; Rosen, N.
    EJC Supplements (2006)

    Fulltext@MSK | Save